Yang Lin, Qiu Xiuliang, Zhao Qiuling, Qiu Hongqiang, Cheng Yu, Liu Wenbin, Xie Ruixiang
Department of Pharmacy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China.
Ann Transl Med. 2022 Aug;10(16):867. doi: 10.21037/atm-22-3577.
BACKGROUND: Ibrutinib, one Food and Drug Administration-approved, orally available, small-molecule Bruton tyrosine kinase (BTK) inhibitor, is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). YouTube is increasingly used for health purposes. However, videos for ibrutinib on YouTube have not been previously evaluated. This study assessed the accuracy and quality of YouTube videos on ibrutinib, to better understand the information shown on a dominant media platform. METHODS: The first 150 video results returned by the YouTube search engine in response to the keyword "ibrutinib" were included (up to June 27, 2022). Typically used predefined inclusion and exclusion criteria were applied to screen the videos based on our needs. A 5-point Global Quality Scale (GQS) determined whether the videos would be useful to patients or not, and the quality of content was analyzed by five content-specific items. The quality of the included videos was classified as "low", "moderate", or "excellent" according to GQS and content score. The median and interquartile range were used to describe the values and Kruskal-Wallis test were used in the analysis. RESULTS: A total of 99 videos with a median of 237 views met the inclusion criteria. The videos were categorized into educational videos (n=6, 6.07%), personal experience and blog (n=3, 3.03%) and interviews videos (n=90, 90.9%). Almost half of the videos were classified as moderate (n=51, 51.51%), followed by excellent (n=25, 25.26%) and low (n=23, 23.23%). Between the groups, no statistically significant differences were observed in the numbers of dislikes, comments, posted days, percentage positivity and viewing rate (P>0.05). There were marked differences in the length, likes, views, viewers' interaction and likeability (P<0.05). CONCLUSIONS: YouTube could be an effective source for different groups of people to obtain helpful information about ibrutinib. The physicians, pharmacists, nurses and healthcare organizations should prepare and upload more comprehensible and reliable videos with evidence-based information.
背景：伊布替尼是一种经美国食品药品监督管理局批准的、口服可用的小分子布鲁顿酪氨酸激酶（BTK）抑制剂，是治疗慢性淋巴细胞白血病（CLL）和套细胞淋巴瘤（MCL）患者的有效靶向疗法。YouTube越来越多地被用于健康目的。然而，此前尚未对YouTube上有关伊布替尼的视频进行评估。本研究评估了YouTube上关于伊布替尼的视频的准确性和质量，以更好地了解一个主流媒体平台上所展示的信息。 方法：纳入YouTube搜索引擎针对关键词“伊布替尼”返回的前150个视频结果（截至2022年6月27日）。根据我们的需求，应用常用的预定义纳入和排除标准来筛选视频。采用5分制全球质量量表（GQS）来确定这些视频对患者是否有用，并通过五个特定内容项目分析内容质量。根据GQS和内容得分，将纳入视频的质量分为“低”、“中等”或“优秀”。使用中位数和四分位数间距来描述数值，并在分析中使用Kruskal-Wallis检验。 结果：共有99个视频符合纳入标准，中位数观看次数为237次。这些视频分为教育视频（n = 6，6.07%）、个人经历和博客（n = 3，3.03%）以及访谈视频（n = 90，90.9%）。几乎一半的视频被归类为中等质量（n = 51，51.51%），其次是优秀质量（n = 25，25.26%）和低质量（n = 23，23.23%）。在各质量组之间，在不喜欢的数量、评论数量、发布天数、积极率和观看率方面未观察到统计学显著差异（P > 0.05）。在视频长度、点赞数、观看次数、观众互动和受欢迎程度方面存在显著差异（P < 0.05）。 结论：YouTube可能是不同人群获取有关伊布替尼有用信息的有效来源。医生、药剂师、护士和医疗保健机构应准备并上传更多内容易懂且可靠的、基于证据的视频。
J Prosthet Dent. 2023-4
J Pediatr Urol. 2021-8
Quintessence Int. 2020
Clin Implant Dent Relat Res. 2023-6
Rheumatol Int. 2021-7
Z Rheumatol. 2024-12
Z Rheumatol. 2023-1
J Adv Pract Oncol. 2021-3
Int J Environ Res Public Health. 2021-2-28
J Community Hosp Intern Med Perspect. 2021-1-26
BMC Public Health. 2020-6-1
J Dermatolog Treat. 2022-2
Quintessence Int. 2020
Zotero 插件